Ag-221 inhibitor – Enasidenib is used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the IDH2 gene, determined by an FDA-approved IDH2 companion diagnostic test.
Description
Ag-221 was developed by Agios Pharmaceuticals.
Server
cloudflare
DNS
View domain name system records, including the A, AAAA, MX and NS records.